Trade Kymera Therapeutics, Inc. - KYMR CFD

Trading Conditions

• Spread: 0.09
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 33.31
• Open: 32.97
• 1-Year Change: -0.21%
• Day's Range: 32.97 - 33.95

Kymera Therapeutics, Inc. Company profile

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation (TPD) platform Pegasus, allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The Company’s Pegasus platform includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling, Quantitative System Pharmacology Model and Chemistry. Its clinical stage programs include IRAK4, IRAKIMiD, and STAT3, which each address targets within the interleukin-1 receptor/toll-like receptor (IL-1R/TLR), and janus kinase/signal transducers and activators of transcription (JAK/STAT). Its programs focus on treating range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Kymera Therapeutics Inc revenues increased from $34M to $72.8M. Net loss applicable to common stockholders increased 83% to $100.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - increase from $59.8M to $125.3M (expense).